本文检索2014年5月29日之前传统药物罗布麻的发明专利，并对这些数据从专利的授权情况、发展趋势、地域分布、竞争国家、竞争机构、疗效配伍等方面进行了整体层面的统计和分析。结果显示，该领域的专利主要来自中、日两国，共764个专利族中只有8个来自其他国家或地区，日本的专利活跃人和申请量均低于中国。企业是专利申请的主力；在专利保护的内容上，以降血压、降血脂等改善心脑血管功能的药理应用以及保健产品的开发为主；与其配伍使用的传统药物类型较为分散，包括活血化瘀药、清热解表药、补虚药和消食药。本研究使用文献学方法，描述了罗布麻专利保护的规律和发展趋势，有利于科研工作者了解罗布麻作为药用植物的研发现状和专利格局，指导未来研究方向。

In this paper, the patents of traditional medicine Apocynum venetum were retrieved till 29th May, 2014, and the patent information, including the authorization condition, developing trends, geographic distribution, competition agencies and therapeutic effects, was analyzed. Totally 764 patent families were obtained, only eight among them coming from countries and districts except China and Japan. China was in a leader position on the number of patent application of A. venetum. The patent applications mainly came from pharmaceutical enterprises. Most frequently patents were about innovations on the pharmacological effects such as regulation of blood pressure and blood sugar, as well as the development of health food and products. Traditional medicines used compatible included blood-activating and stasis-eliminating drugs, heat-clearing drugs, diaphoretics, deficiency-nourishing drugs and digestive drugs. This article revealed the trend and some rules of development of A. venetum, and reflected the developmental achievement and world patent pattern after a meta-analysis, exhorting to guide a better understanding and further research.

北京市科学技术委员会“首都市民健康项目培育”项目（Z131100006813045）：生物药物专利信息服务系统研发，负责人：孙瑞阳。